tetano
Editor, Senior Moderator
Am J Transplant
. 2022 Sep 9.
doi: 10.1111/ajt.17195. Online ahead of print.
Pediatric Solid Organ Transplant Recipients Demonstrate Robust Cell-Mediated and Humoral Responses to 3 Doses of mRNA SARS-CoV-2 Vaccine
Julia S Bratic[SUP] 1 [/SUP], Hayley A Gans[SUP] 2 [/SUP], Sharon F Chen[SUP] 2 [/SUP], Niaz Banaei[SUP] 3 [/SUP], Erica M Johnston[SUP] 4 [/SUP], Katherine Sear[SUP] 5 [/SUP], Sarah Samreth[SUP] 1 [/SUP], Sruti S Nadimpalli[SUP] 2 [/SUP]
Affiliations
Abstract
Pediatric solid organ transplant recipients (pSOTR) often demonstrate suboptimal vaccine responses and are not included in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccine efficacy trials. This population has shown variable humoral immunity following SARS-CoV-2 vaccination, and no studies have assessed cell-mediated responses after SARS-CoV-2 vaccination in pSOTR. SARS-CoV2-specific interferon-gamma release assay (IGRA), immunoglobulin G (IgG), and receptor-binding domain (RBD)-ACE2 blocking antibody (Ab), were measured in pSOTR aged 5-17 years after 2-3 doses of SARS-CoV-2 mRNA vaccine. Thirty-three subjects were included, with 25 tested after the 2[SUP]nd[/SUP] dose of mRNA vaccine (V2) and 21 tested after the 3[SUP]rd[/SUP] dose of mRNA vaccine (V3). Of the 19 subjects who had IgG testing after V3, 100.0% (19/19) had a positive IgG response. Of the 17 subjects who had IGRA testing after V3, 94.1% (16/17) had a positive IGRA response. RBD-ACE2 blocking antibody increased significantly from V2 to V3 (p=0.007). Subjects <1 year from transplant demonstrated a significantly larger increase in RBD-ACE2 blocking Ab from V2 to V3 than did those >1 year from transplant (p=0.05). SARS-CoV-2 vaccination induces humoral and cell-mediated responses in the majority of pSOTR, with improved quantitative humoral response after 3 doses.
. 2022 Sep 9.
doi: 10.1111/ajt.17195. Online ahead of print.
Pediatric Solid Organ Transplant Recipients Demonstrate Robust Cell-Mediated and Humoral Responses to 3 Doses of mRNA SARS-CoV-2 Vaccine
Julia S Bratic[SUP] 1 [/SUP], Hayley A Gans[SUP] 2 [/SUP], Sharon F Chen[SUP] 2 [/SUP], Niaz Banaei[SUP] 3 [/SUP], Erica M Johnston[SUP] 4 [/SUP], Katherine Sear[SUP] 5 [/SUP], Sarah Samreth[SUP] 1 [/SUP], Sruti S Nadimpalli[SUP] 2 [/SUP]
Affiliations
- PMID: 36083190
- DOI: 10.1111/ajt.17195
Abstract
Pediatric solid organ transplant recipients (pSOTR) often demonstrate suboptimal vaccine responses and are not included in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccine efficacy trials. This population has shown variable humoral immunity following SARS-CoV-2 vaccination, and no studies have assessed cell-mediated responses after SARS-CoV-2 vaccination in pSOTR. SARS-CoV2-specific interferon-gamma release assay (IGRA), immunoglobulin G (IgG), and receptor-binding domain (RBD)-ACE2 blocking antibody (Ab), were measured in pSOTR aged 5-17 years after 2-3 doses of SARS-CoV-2 mRNA vaccine. Thirty-three subjects were included, with 25 tested after the 2[SUP]nd[/SUP] dose of mRNA vaccine (V2) and 21 tested after the 3[SUP]rd[/SUP] dose of mRNA vaccine (V3). Of the 19 subjects who had IgG testing after V3, 100.0% (19/19) had a positive IgG response. Of the 17 subjects who had IGRA testing after V3, 94.1% (16/17) had a positive IGRA response. RBD-ACE2 blocking antibody increased significantly from V2 to V3 (p=0.007). Subjects <1 year from transplant demonstrated a significantly larger increase in RBD-ACE2 blocking Ab from V2 to V3 than did those >1 year from transplant (p=0.05). SARS-CoV-2 vaccination induces humoral and cell-mediated responses in the majority of pSOTR, with improved quantitative humoral response after 3 doses.